Effectiveness of UNAIDS targets and HIV vaccination across 127 countries - PubMed (original) (raw)
Effectiveness of UNAIDS targets and HIV vaccination across 127 countries
Jan Medlock et al. Proc Natl Acad Sci U S A. 2017.
Abstract
The HIV pandemic continues to impose enormous morbidity, mortality, and economic burdens across the globe. Simultaneously, innovations in antiretroviral therapy, diagnostic approaches, and vaccine development are providing novel tools for treatment-as-prevention and prophylaxis. We developed a mathematical model to evaluate the added benefit of an HIV vaccine in the context of goals to increase rates of diagnosis, treatment, and viral suppression in 127 countries. Under status quo interventions, we predict a median of 49 million [first and third quartiles 44M, 58M] incident cases globally from 2015 to 2035. Achieving the Joint United Nations Program on HIV/AIDS 95-95-95 target was estimated to avert 25 million [20M, 33M] of these new infections, and an additional 6.3 million [4.8M, 8.7M] reduction was projected with the 2020 introduction of a 50%-efficacy vaccine gradually scaled up to 70% coverage. This added benefit of prevention through vaccination motivates imminent and ongoing clinical trials of viable candidates to realize the goal of HIV control.
Keywords: HIV; effectiveness; mathematical model; vaccination.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Fig. 1.
Infections averted between 2015 and 2035, compared with maintaining status quo diagnosis, treatment, and viral suppression, by the UNAIDS 95–95–95 target (Top); rollout of vaccination in 2020 while maintaining status quo levels of diagnosis, treatment, and viral suppression (Middle); and the UNAIDS 95–95–95 target combined with 2020 vaccination rollout (Bottom). Predictions are medians over 1,000 model simulations in which parameter values were sampled from data-driven distributions. See SI Appendix, Figs. S4–S140 for projections and uncertainty estimation globally, by region, and by country.
Fig. 2.
Effectiveness of HIV interventions globally (Left) and for selected countries (remaining columns) in terms of cumulative incidence (top row), annual incidence per million population (second row), PLHIV (third row), and cumulative HIV mortality (bottom row). Predictions are medians over 1,000 model simulations in which parameter values were sampled from data-driven distributions. See SI Appendix, Figs. S4–S140 for median and uncertainty estimates of effectiveness of HIV interventions for all 127 countries.
Fig. 3.
Effectiveness of HIV interventions for UNAIDS regions in terms of cumulative incidence from 2015 to 2035 (Upper) and number of PLHIV in 2035 (Lower). Medians (colored bars) and first and third quartiles (black error bars) were generated from 1,000 model simulations in which parameter values were sampled from data-driven distributions. See SI Appendix, Figs. S4–S140 for median and uncertainty estimates of the effectiveness of HIV interventions for UNAIDS regions.
Fig. 4.
Scenario analysis for vaccination under six strategies, globally (Left) and for selected countries (remaining columns), with variation in vaccine efficacy, ultimate coverage, initiation date of vaccination rollout, and rate of scale-up. Vaccine scenario projections are generated from simulations parametrized with modal values.
Comment in
- Preventing acquisition of HIV is the only path to an AIDS-free generation.
Corey L, Gray GE. Corey L, et al. Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3798-3800. doi: 10.1073/pnas.1703236114. Epub 2017 Mar 30. Proc Natl Acad Sci U S A. 2017. PMID: 28360202 Free PMC article. No abstract available.
Similar articles
- Impact and Cost of Scaling Up Voluntary Medical Male Circumcision for HIV Prevention in the Context of the New 90-90-90 HIV Treatment Targets.
Kripke K, Reed J, Hankins C, Smiley G, Laube C, Njeuhmeli E. Kripke K, et al. PLoS One. 2016 Oct 26;11(10):e0155734. doi: 10.1371/journal.pone.0155734. eCollection 2016. PLoS One. 2016. PMID: 27783681 Free PMC article. - Exploring the Potential Health Impact and Cost-Effectiveness of AIDS Vaccine within a Comprehensive HIV/AIDS Response in Low- and Middle-Income Countries.
Harmon TM, Fisher KA, McGlynn MG, Stover J, Warren MJ, Teng Y, Näveke A. Harmon TM, et al. PLoS One. 2016 Jan 5;11(1):e0146387. doi: 10.1371/journal.pone.0146387. eCollection 2016. PLoS One. 2016. PMID: 26731116 Free PMC article. - Population-level impact of an accelerated HIV response plan to reach the UNAIDS 90-90-90 target in Côte d'Ivoire: Insights from mathematical modeling.
Maheu-Giroux M, Vesga JF, Diabaté S, Alary M, Baral S, Diouf D, Abo K, Boily MC. Maheu-Giroux M, et al. PLoS Med. 2017 Jun 15;14(6):e1002321. doi: 10.1371/journal.pmed.1002321. eCollection 2017 Jun. PLoS Med. 2017. PMID: 28617810 Free PMC article. - Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.
Ferrantelli F, Buttò S, Cafaro A, Wahren B, Ensoli B. Ferrantelli F, et al. Springer Semin Immunopathol. 2006 Nov;28(3):289-301. doi: 10.1007/s00281-006-0026-3. Epub 2006 Sep 16. Springer Semin Immunopathol. 2006. PMID: 16983452 Review. - Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines.
Blower S, Schwartz EJ, Mills J. Blower S, et al. AIDS Rev. 2003 Apr-Jun;5(2):113-25. AIDS Rev. 2003. PMID: 12876900 Review.
Cited by
- Prevalence and factors associated with hyperglycemia among persons living with HIV/AIDS on dolutegravir-based antiretroviral therapy in Uganda.
Byereta LH, Olum R, Mutebi EI, Kalyesubula R, Kagimu M, Meya DB, Andia-Biraro I. Byereta LH, et al. Ther Adv Infect Dis. 2024 Sep 10;11:20499361241272630. doi: 10.1177/20499361241272630. eCollection 2024 Jan-Dec. Ther Adv Infect Dis. 2024. PMID: 39286262 Free PMC article. - Human Immunodeficiency Virus Vaccine: Promise and Challenges.
Graciaa DS, Walsh SR, Rouphael N. Graciaa DS, et al. Infect Dis Clin North Am. 2024 Sep;38(3):475-485. doi: 10.1016/j.idc.2024.04.004. Epub 2024 Jun 13. Infect Dis Clin North Am. 2024. PMID: 38876903 Review. - Infectious Disease Modelling of HIV Prevention Interventions: A Systematic Review and Narrative Synthesis of Compartmental Models.
Giddings R, Indravudh P, Medley GF, Bozzani F, Gafos M, Malhotra S, Terris-Prestholt F, Torres-Rueda S, Quaife M. Giddings R, et al. Pharmacoeconomics. 2023 Jun;41(6):693-707. doi: 10.1007/s40273-023-01260-z. Epub 2023 Mar 29. Pharmacoeconomics. 2023. PMID: 36988896 Free PMC article. - Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact.
Gregg EW, Buckley J, Ali MK, Davies J, Flood D, Mehta R, Griffiths B, Lim LL, Manne-Goehler J, Pearson-Stuttard J, Tandon N, Roglic G, Slama S, Shaw JE; Global Health and Population Project on Access to Care for Cardiometabolic Diseases. Gregg EW, et al. Lancet. 2023 Apr 15;401(10384):1302-1312. doi: 10.1016/S0140-6736(23)00001-6. Epub 2023 Mar 14. Lancet. 2023. PMID: 36931289 Free PMC article. - Strengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection.
Eller AJ, DiDomizio EE, Madden LM, Oliva JD, Altice FL, Johnson KA. Eller AJ, et al. Ann Med. 2022 Dec;54(1):1714-1724. doi: 10.1080/07853890.2022.2084154. Epub 2022 Jul 1. Ann Med. 2022. PMID: 35775786 Free PMC article.
References
- Fauci AS, Folkers GK. Investing to meet the scientific challenges of HIV/AIDS. Health Aff (Millwood) 2009;28(6):1629–1641. - PubMed
- Folkers GK, Fauci AS. Controlling and ultimately ending the HIV/AIDS pandemic: A feasible goal. JAMA. 2010;304(3):350–351. - PubMed
- Fauci AS, Marston HD. Focusing to achieve a world without AIDS. JAMA. 2015;313(4):357–358. - PubMed
- UNAIDS 2014 90–90–90: An ambitious treatment target to help end the AIDS epidemic. Available at www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf. Accessed August 22, 2016.
- UNAIDS 2014 Fast-track: Ending the AIDS epidemic by 2030. Available at www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf. Accessed August 16, 2016.
Publication types
MeSH terms
Substances
Grants and funding
- T32 AI007404/AI/NIAID NIH HHS/United States
- U01 GM070694/GM/NIGMS NIH HHS/United States
- U01 GM087719/GM/NIGMS NIH HHS/United States
- U01 GM105627/GM/NIGMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical